Key Highlights: Implications: The new indication firmly positions durvalumab as a frontline immunotherapy option in advanced liver cancer, giving oncologists a more con...
Key Highlights: Implications: Oncology ace Vanneste turbocharges MSD’s immuno-oncology push against Roche/Pfizer, targeting India’s exploding cancer caseload with ke...
Key Highlights: Implications: Nubeqa’s India approval intensifies mHSPC competition against Janssen’s Erleada, amid prostate therapeutics market growing at 8.2% CAGR to $739M by 2030. ...
Key Highlights: Implications: Imfinzi storms endometrial cancer protocols, giving oncologists a potent immunotherapy combo that leapfrogs chemo-only standards. AstraZeneca doubles do...
Key Highlights: Implications: Durvalumab storms earlier gastric cancer treatment, snatching share from chemo-only protocols as oncologists embrace immunotherapy combo superiority.&nb...
Key Highlights: Implications: Tishtha detonates pricing bombs on Roche’s Tecentriq and MSD’s Opdivo, handing cash-strapped hospitals a lifeline while exploding p...
